However, p38 MAPK activation in CD8+ T cells compromises the anti-tumor efficacy of some anti-PD-L1 therapies, indicating that a combination of anti-PD-L1 and p38 MAPK-targeted therapies may hold potential (192). Here, CD8A is linked to neoplasm.